Cargando…

Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase

We evaluated the impact of revised Clinical and Laboratory Standards Institute (CLSI) breakpoints for broad-spectrum cephalosporins (BSCs) on the susceptibilities of 1,742 isolates of Enterobacter species, Serratia marcescens, Citrobacter freundii, and Morganella morganii. The 2011 CLSI criteria for...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ki-Ho, Chong, Yong Pil, Kim, Sung-Han, Lee, Sang-Oh, Lee, Mi Suk, Sung, Heungsup, Kim, Mi-Na, Kim, Yang Soo, Woo, Jun Hee, Choi, Sang-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382052/
https://www.ncbi.nlm.nih.gov/pubmed/28271652
http://dx.doi.org/10.3947/ic.2017.49.1.62
_version_ 1782520038051282944
author Park, Ki-Ho
Chong, Yong Pil
Kim, Sung-Han
Lee, Sang-Oh
Lee, Mi Suk
Sung, Heungsup
Kim, Mi-Na
Kim, Yang Soo
Woo, Jun Hee
Choi, Sang-Ho
author_facet Park, Ki-Ho
Chong, Yong Pil
Kim, Sung-Han
Lee, Sang-Oh
Lee, Mi Suk
Sung, Heungsup
Kim, Mi-Na
Kim, Yang Soo
Woo, Jun Hee
Choi, Sang-Ho
author_sort Park, Ki-Ho
collection PubMed
description We evaluated the impact of revised Clinical and Laboratory Standards Institute (CLSI) breakpoints for broad-spectrum cephalosporins (BSCs) on the susceptibilities of 1,742 isolates of Enterobacter species, Serratia marcescens, Citrobacter freundii, and Morganella morganii. The 2011 CLSI criteria for cefotaxime and ceftazidime reduced the rates of susceptibility by 2.9% and 5.9%, respectively. The 2014 CLSI criteria for cefepime reduced the rate of susceptibility by 13.9%, and categorized 11.8% isolates as susceptible-dose dependent (SDD) for cefepime. Among 183 isolates with extended-spectrum ß-lactamase (ESBL) phenotype, implementation of the new criteria reduced the rates of susceptibility to cefotaxime, ceftazidime, and cefepime by 2.8%, 14.8%, and 53.6%, respectively. The proportion of ESBL phenotype among BSC-susceptible isolates was low (0.9% for cefotaxime, 3.0% for ceftazidime, and 3.3% for cefepime). In summary, implementation of new CLSI criteria led to little change in susceptibility to cefotaxime and ceftazidime but a substantial change in susceptibility to cefepime. The recognition of revised CLSI criteria for BSC and SDD will help clinicians to select the optimal antibiotic and dosing regimen.
format Online
Article
Text
id pubmed-5382052
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Society of Infectious Diseases and Korean Society for Chemotherapy
record_format MEDLINE/PubMed
spelling pubmed-53820522017-04-06 Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase Park, Ki-Ho Chong, Yong Pil Kim, Sung-Han Lee, Sang-Oh Lee, Mi Suk Sung, Heungsup Kim, Mi-Na Kim, Yang Soo Woo, Jun Hee Choi, Sang-Ho Infect Chemother Brief Communication We evaluated the impact of revised Clinical and Laboratory Standards Institute (CLSI) breakpoints for broad-spectrum cephalosporins (BSCs) on the susceptibilities of 1,742 isolates of Enterobacter species, Serratia marcescens, Citrobacter freundii, and Morganella morganii. The 2011 CLSI criteria for cefotaxime and ceftazidime reduced the rates of susceptibility by 2.9% and 5.9%, respectively. The 2014 CLSI criteria for cefepime reduced the rate of susceptibility by 13.9%, and categorized 11.8% isolates as susceptible-dose dependent (SDD) for cefepime. Among 183 isolates with extended-spectrum ß-lactamase (ESBL) phenotype, implementation of the new criteria reduced the rates of susceptibility to cefotaxime, ceftazidime, and cefepime by 2.8%, 14.8%, and 53.6%, respectively. The proportion of ESBL phenotype among BSC-susceptible isolates was low (0.9% for cefotaxime, 3.0% for ceftazidime, and 3.3% for cefepime). In summary, implementation of new CLSI criteria led to little change in susceptibility to cefotaxime and ceftazidime but a substantial change in susceptibility to cefepime. The recognition of revised CLSI criteria for BSC and SDD will help clinicians to select the optimal antibiotic and dosing regimen. The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2017-03 2017-02-28 /pmc/articles/PMC5382052/ /pubmed/28271652 http://dx.doi.org/10.3947/ic.2017.49.1.62 Text en Copyright © 2017 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Park, Ki-Ho
Chong, Yong Pil
Kim, Sung-Han
Lee, Sang-Oh
Lee, Mi Suk
Sung, Heungsup
Kim, Mi-Na
Kim, Yang Soo
Woo, Jun Hee
Choi, Sang-Ho
Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase
title Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase
title_full Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase
title_fullStr Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase
title_full_unstemmed Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase
title_short Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase
title_sort impact of revised broad-spectrum cephalosporin clinical and laboratory standards institute breakpoints on susceptibility in enterobacteriaceae producing ampc β-lactamase
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382052/
https://www.ncbi.nlm.nih.gov/pubmed/28271652
http://dx.doi.org/10.3947/ic.2017.49.1.62
work_keys_str_mv AT parkkiho impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT chongyongpil impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT kimsunghan impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT leesangoh impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT leemisuk impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT sungheungsup impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT kimmina impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT kimyangsoo impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT woojunhee impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase
AT choisangho impactofrevisedbroadspectrumcephalosporinclinicalandlaboratorystandardsinstitutebreakpointsonsusceptibilityinenterobacteriaceaeproducingampcblactamase